Onsaeng Inc. is a Korean consumer brand company.
SEOUL · REPUBLIC OF KOREA CONSUMER HEALTH BRAND DEVELOPMENT
We build consumer health brands that can survive scrutiny.
Onsaeng develops beauty and wellness programs from the consumer need outward—connecting product logic, partner capability, evidence, and commercialization before a promise reaches the market.
WHAT IS TRUE TODAY
Clarity before theatre.
Our current men's-health oral-solid program is in partner and feasibility screening.
Initial conversations disclose enough to evaluate capability—not confidential composition.
No candidate site, material, performance, or partnership is treated as confirmed without written product-specific evidence.
THE ONSAENG MODEL
One system.
Four disciplines.
Consumers experience one product, not a collection of departments. We structure the work the same way.
Consumer intelligence
We translate a specific consumer tension into a product brief, an experience standard, and the questions that must be answered before launch.
Product system design
Positioning, formulation hypotheses, delivery experience, packaging, and commercial logic are developed as one connected system.
Evidence architecture
Every material claim is mapped to its required source, owner, document, test, and release gate before it reaches a customer.
Partner orchestration
We bring technical, regulatory, ingredient, manufacturing, and market partners into one decision path with clear disclosure boundaries.
FROM DESIRE TO DELIVERY
The work moves in one direction.
- 01DISCOVER
Find the unresolved consumer need and the belief structure surrounding it.
- 02DESIGN
Turn that need into a differentiated product and evidence specification.
- 03VALIDATE
Ask qualified partners to test feasibility, rights, quality, and route to market.
- 04BUILD
Advance only the system that survives technical and commercial scrutiny.
CONFIDENTIAL DEVELOPMENT PROGRAM / KOREA
A once-daily oral-solid program, currently being qualified.
We are evaluating specialist partners for a low-dose program intended for the Republic of Korea. Detailed active identity, candidate composition, and proprietary delivery hypotheses are shared only after the appropriate confidentiality path is agreed.
- PROGRAM
- Once-daily, low-dose oral solid
- MARKET
- Republic of Korea
- CURRENT STAGE
- Pre-NDA capability screening
- DECISION STANDARD
- Technical fit · rights · evidence · Korea pathway · commercial fit
01NDA
02FEASIBILITY
03PILOT
04VALIDATION
05COMMERCIALIZATION
PARTNER PROFILE
What we are looking for.
We value precise answers, explicit limits, and a documented path from public capability to product-specific commitment.
Development & manufacturing
Oral-solid development, low-dose uniformity, bioavailability strategy, analytical work, scale-up, packaging, and Korea-facing CMC support.
Ingredient & rights
Authenticated materials, specifications, data packages, supply continuity, market rights, trademark terms, and combination-use review.
Regulatory & evidence
Korean pathway assessment, claim boundaries, study design, product-specific validation, documentation, and release-readiness review.
Our working boundary
Capability statements are not product commitments. Candidate ingredients are not finished-product evidence. Development hypotheses are not clinical claims. We move each statement forward only when the matching document, agreement, batch, or test exists.
BUILD WITH US